EGFR and non-small cell lung carcinoma: The results of the ADJUVANT-CTONG 1104 trial showed that, compared with chemotherapy and historical data, patients with stage II/III NSCLC with an EGFR mutation who receive adjuvant therapy with gefitinib had improved DFS and the longest OS (8, 29).